Article
Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.
Future medicinal chemistry - 1 May 2016
Lim Sang Min, Jeong Yujeong, Hong Sungwoo
Abstract excerpt
Deregulation of EGFR is involved in the development of many cancers. The inhibition of EGFR kinase activity has been clinically validated as a promising approach for the treatment of non-small-cell lung cancer (NSCLC). However, all NSCLC patients who initially benefited from first-generation EGFR inhibitors eventually develop drug resistance. A point mutation at the gatekeeper position, T790M in EGFR kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.